SCHEMBL3394660

SCHEMBL3394660

CCC(CC)n1c(O)nc2ncc(Cl)c(-c3cccc(C(=O)OC)c3)c21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK8 P49336 1/20 0.41
NR1H2 P55055 1/20 0.40
NR1H3 Q13133 1/20 0.40
NR1H4 Q96RI1 2/20 0.39
TGFBR1 P36897 1/20 0.38
DHFR P00374 2/20 0.37
GABRG2 P18507 1/20 0.37
GABRB3 P28472 1/20 0.37
GABRA5 P31644 1/20 0.37
GABRA3 P34903 1/20 0.37
NPC1 O15118 1/20 0.36
KDM5B Q9UGL1 1/20 0.36
NEK1 Q96PY6 1/20 0.36
AXL P30530 1/20 0.36
ERN1 O75460 2/20 0.36
DGAT2 Q96PD7 1/20 0.36
PAK1 Q13153 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.35
ABL1 P00519 1/20 0.35
BCR P11274 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2300505 0.93 DHFR (0.38) CDK8NR1H2NR1H3NR1H4TGFBR1
SCHEMBL2296331 0.86 CYP3A4 (0.40) NR1H2NR1H3ERN1
SCHEMBL2302530 0.84 DHFR (0.37) DHFR
SCHEMBL2297388 0.82 JAK2 (0.38)
SCHEMBL13007669 0.81 ALDH1A1 (0.33) NPC1
SCHEMBL2298152 0.81 DYRK1A (0.38) CDK8NR1H4
SCHEMBL3394667 0.81 LMNA (0.41) CDK8NR1H2NR1H3NR1H4TGFBR1
SCHEMBL2297424 0.81 AURKA (0.43) L3MBTL1
SCHEMBL2299846 0.80 VDR (0.36) NR1H4NPC1PLAU
SCHEMBL3397374 0.79 NR1H2 (0.37) NR1H2NR1H3TGFBR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110312975-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS YANG ZHE (US) 2011-12-22 US claimed
EP-2244711-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS Cytokinetics, Incorporated (US) 2010-11-03 EP claimed
US-20090253737-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INCORPORATED 2009-10-08 US claimed
WO-2009099594-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED (US) 2009-08-13 WO claimed
US-20110312975-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS YANG ZHE (US) 2011-12-22 US disclosed
US-20110312975-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS YANG ZHE (US) 2011-12-22 US disclosed
EP-2244711-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS Cytokinetics, Incorporated (US) 2010-11-03 EP disclosed
WO-2009099594-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED (US) 2009-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253737-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS TNNC1, TNNI3, TNNT2 CDK8 2492/4885NR1H2 3171/4885NR1H3 3118/4885
US-20110312975-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS TNNC1, TNNI3, TNNT2 CDK8 2523/4885NR1H2 2883/4885NR1H3 2832/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.